21 Mar 2023
Bionow Awards 2022
The 2022 Bionow Awards took place on 16th March 2023 in the super hangar of the iconic Concorde at Manchester Airport as attendees celebrated the very best of the life sciences industry.
The competition was once again tough and featured two brand-new categories, with the judges being presented with a very high calibre of shortlisted companies and individuals across all of the awards.
Health Innovation Manchester was delighted to sponsor the Product Of The Year Award alongside the Innovation Agency and Yorkshire and Humber AHSN
Richard Deed, Associate Commercial Director of Industry at Health Innovation Manchester, said:
“The Bionow Awards always shine a light on a wide variety of talent, and it has now become a real landmark event on the life sciences calendar. All of the nominees and the winners on the evening showcased cutting-edge innovation, ingenuity, and most importantly solutions to real-world issues that we are facing across the healthcare and life sciences sectors, with many of the shortlisted applicants and winners having worked with AHSNs.
“I’d like to once again congratulate all of the nominees and the winners in each of the award’s categories. I am sure that these awards will continue to showcase the very best that the life science industry has to offer.”
Dr Geoff Davison, CEO of Bionow, said:
“It’s great to be back at the Concorde Conference Centre to commemorate another amazing year for the North within the life sciences sector. The judging panel were particularly impressed with the calibre of the entries, and it has been very difficult to choose winners as the standard was so high. Congratulations to all the nominees and the winners in particular.”
Bionow Awards 2022 Winners
Viveca Biomed is a rapidly growing specialist female healthcare business, that provides sufferers of bladder leakage a new quality of life. The product has recently gained NHS approval and is exported to over 20 countries.
Judged on the quality of the company product, service or R&D initiative and acknowledging the potential for growth, Viveca Biomed has already raised money, commercialised the technology quickly and offered a clear female global public health benefit.
University of Manchester’s DETERMINE initiative
The Bionow Healthcare Project of the Year Award was intended to recognise high quality innovative healthcare projects, and the winner of this category, demonstrated this as an innovative multi-drug pan-cancer platform trial providing access to and evaluating targeted therapies outside their licensed indications, helping to identify treatments for those with rare cancers.
CPI’s Soteria project
Identifying high quality innovative projects or R&D initiatives which address important technical challenges, the Bionow Project of the Year Award went to the CPI’s Soteria project, which involved the formulation, scale up and manufacture of an oral drug (GMP) for inflammatory bowel disease, which could potentially allow the patient to take a targeted medication at home.
Crest Solutions for the CXV Global SmartFactory LineClearance AssistantTM
Recognising the recipient of the Bionow Product of the Year Award for developing a highly innovative product which addresses a definite need in the healthcare industry, as well as their collaboration with five tier 1 global life science organisations, the accolade went to Crest Solutions for the CXV Global SmartFactory LineClearance AssistantTM, an innovative solution which digitalises the pharma and medical device line clearance process during packaging operations.
Rapid Fluidics provides microfluidic design, prototyping and manufacturing services using a novel approach to produce microfluidic test cards with a next-day turnaround.
The Bionow Technical Service Award winner identified the use of 3D printing to enable their customers to try multiple versions of early-stage designs in a very short space of time, reducing the time and cost of diagnostic product development.
Medicines Discovery Catapult’s Psychiatry Consortium
Medicines Discovery Catapult’s Psychiatry Consortium is a strategic collaboration of two leading medical research charities, eight pharmaceutical companies and two contract research organisations.
The recipient of the new Bionow Partnership & Collaboration Award was able to describe a large collaboration between an impressive number of multinational organisations, all focused on an area of unmet clinical need. Having already leveraged more than £4 million in research funding to address the challenges of living with mental health conditions.
In recognition of an exceptional individual within the first five years of their life science career and having demonstrated a significant contribution to their current role, the Bionow Rising Star Award recipient, Kimberly Rockley of ApconiX, demonstrated leadership and business development skills as well as cutting edge research into human-based in-vitro assays, contributing to the launch of two commercial assays, one of which is an innovative approach to seizure detection.
F2G’s collaboration with Shionogi
The Bionow Investment Deal Award winner stood out in both scale and potential impact. Developing and commercialising a new antifungal agent for invasive fungal infections in Europe and Asia, including $100 million upfront payment, shared development costs and a commitment of up to $380 million in regulatory and commercial milestones, F2G’s collaboration with Shionogi won top prize.
Seda Pharmaceutical Development Services
Another new category for 2022, the Bionow Business Growth Award identified a recipient who demonstrated growth in all the areas considered, including profit, headcount and facilities. Seda Pharmaceutical Development Services’ sustained growth has enabled a significant financial investment of around £4 million in new facilities to enhance their capabilities, capacity and working environment for their team.
Recognising export successes and with a significant proportion of their sales in international markets, the Bionow Export Award winner has shown very significant export growth of 88% over the last 3 years and are exporting to significant markets across the globe.
Navigating the significant challenges of Brexit and with significant investment in their UK site, CSL Seqirus has continued to innovate its seasonal influenza vaccine, increasing annual export revenues to nearly $1bn during the pandemic.
The Bionow Outstanding Contribution Award recognises an exceptional individual who has made a significant contribution to the sector throughout their career. This year’s recipient was Prof Claire Thompson, CEO of Agility Life Sciences and an entrepreneur with more than 20 years of experience in the pharmaceutical industry, with titles including Entrepreneur in Residence at the University of Cambridge, Honorary Professor at the University of Nottingham and founder and funder of the Girls In Football Teams (GIFT) Grant initiative.
With a passion for demonstrating to girls where science can take them and about providing opportunities for women and girls to excel, Claire also Chairs the global FIPWiSE (Women in Science and Education) initiative to engage, enable and empower girls and women.
Representing a leading, globally formidable company which has demonstrated significant progress year after year whilst also demonstrating notable progress during the past 12 months, the Bionow Company of the Year Award went to CSL Seqirus. The organisation has contributed significantly to their local economy and has secured significant recent investments to develop their capabilities, as well as into the wellbeing of their staff.
The final accolade of the evening was the Bionow Lifetime Achievement Award, which was given to John Stageman CBE, Chair of Bionow. After a long and distinguished career at AstraZeneca and its forerunners, John has held many influential positions including as a member of the BBSRC Research Council, Chairman of the Biomedical Catalyst and Chairman of LifeArc.
More locally he has been a Governor of the University of Manchester and a member of the Steering Board of Health Innovation Manchester. John was awarded an OBE for services to the UK Biotechnology Industry in 2011 and an MBE in 2022 for services to the Translation of Medical Research.